Future Perspectives for the Treatment of Pulmonary Arterial Hypertension

Journal of the American College of Cardiology

Volumn 54, Issue 1 SUPPL. 1, 2009, Pages

  Ghofrani, Hossein A ^a,j   Barst, Robyn J ^b   Benza, Raymond L ^c   Champion, Hunter C ^d   Fagan, Karen A ^e   Grimminger, Friedrich ^a,j   Humbert, Marc ^f   Simonneau, Gérald ^f   Stewart, Duncan J ^g   Ventura, Carlo ^h   Rubin, Lewis J ⁱ  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b Columbia University ^*  (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF SOUTH ALABAMA   (United States)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY HOSPITAL GIESSEN   (Germany)

more..

Author keywords

PAH; pulmonary arterial hypertension; treatment

Indexed keywords

ANGIOPOIETIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; RAPAMYCIN; SILDENAFIL; SORAFENIB; VASCULOTROPIN;

ANTIANGIOGENIC THERAPY; CLINICAL RESEARCH; DRUG RESEARCH; DRUG TARGETING; EXPERIMENTAL STUDY; GENE THERAPY; GENETIC VARIABILITY; HEART RIGHT VENTRICLE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; STEM CELL TRANSPLANTATION;

CHRONIC DISEASE; ENDOTHELINS; ENDOTHELIUM, VASCULAR; GTP-BINDING PROTEINS; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; NADP; NATRIURETIC PEPTIDES; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; PLATELET-DERIVED GROWTH FACTOR; POLYMORPHISM, GENETIC; REACTIVE OXYGEN SPECIES; STEM CELLS; VENTRICULAR REMODELING;

EID: 67649849917     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.04.014     Document Type: Review

References (136)

1. Willette R.N., Gu J.L., Lysko P.G., Anderson K.M., Minehart H., and Yue T. BMP-2 gene expression and effects on human vascular smooth muscle cells. J Vasc Res 36 (1999) 120-125
2. Nakaoka T., Gonda K., Ogita T., et al. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J Clin Invest 100 (1997) 2824-2832
3. Morrell N.W., Yang X., Upton P.D., et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-β 1 and bone morphogenetic proteins. Circulation 104 (2001) 790-795
4. Cogan J.D., Pauciulo M.W., Batchman A.P., et al. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med 174 (2006) 590-598
5. Trembath R.C., and Harrison R. Insights into the genetic and molecular basis of primary pulmonary hypertension. Pediatr Res 53 (2003) 883-888
6. Deng Z., Morse J.H., Slager S.L., et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67 (2000) 737-744
7. Thomson J.R., Machado R.D., Pauciulo M.W., et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J Med Genet 37 (2000) 741-745
8. Cogan J.D., Vnencak-Jones C.L., and Phillips III J.A. Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension. Genet Med 7 (2005) 169-174
9. Machado R.D., Pauciulo M.W., Thomson J.R., et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68 (2001) 92-102
10. Runo J.R., and Loyd J.E. Primary pulmonary hypertension. Lancet 361 (2003) 1533-1544
11. Sztrymf B., Coulet F., Girerd B., et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 177 (2008) 1377-1383
12. Rosenzweig E.B., Morse J.H., Knowles J.A., et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant 27 (2008) 668-674
13. Thompson J., Machado R., Pauciulo N., et al. Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein type II receptor (abstr). J Heart Lung Transplant 20 (2001) 149
14. Kawabata M., Imamura T., and Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 9 (1998) 49-61
15. Massagué J., Seoane J., and Wotton D. Smad transcription factors. Genes Dev 19 (2005) 2783-2810
16. Shi Y., and Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113 (2003) 685-700
17. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425 (2003) 577-584
18. Cullingworth J., Hooper M.L., Harrison D.J., et al. Carcinogen-induced pancreatic lesions in the mouse: effect of Smad4 and Apc genotypes. Oncogene 21 (2002) 4696-4701
19. de Bosscher K., Hill C.S., and Nicolas F.J. Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells. Biochem J 379 (2004) 209-216
20. Maliekal T.T., Antony M.L., Nair A., Paulmurugan R., and Karunagaran D. Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer. Oncogene 22 (2003) 4889-4897
21. de Winter J.P., Roelen B.A., ten Dijke P., van der Burg B., and van den Eijnden-van Raaij A.J. DPC4 (SMAD4) mediates transforming growth factor-β1 (TGF-β1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene 14 (1997) 1891-1899
22. Moren A., Itoh S., Moustakas A., ten Dijke P., and Heldin C.H. Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4. Oncogene 19 (2000) 4396-4404
23. Haynes W.G., and Webb D.J. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16 (1998) 1081-1098
24. Sakurai T., Yanagisawa M., Takuwa Y., et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348 (1990) 732-735
25. Arai H., Hori S., Aramori I., Ohkubo H., and Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348 (1990) 730-732
26. Zamora M.A., Dempsey E.C., Walchak S.J., and Stelzner T.J. BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 9 (1993) 429-433
27. Sato K., Oka M., Hasunuma K., Ohnishi M., Sato K., and Kira S. Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. Am J Physiol 269 (1995) L668-L672
28. Breceptor-mediated NO synthesis in hypertensive rat lungs. Am J Physiol Lung Cell Mol Physiol 276 (1999) L571-L581
29. Nicaud V., Poirier O., Behague I., et al. Polymorphisms of the endothelin-A and -B receptor genes in relation to blood pressure and myocardial infarction: the Etude Cas-Témoins sur l'Infarctus du Myocarde (ECTIM) Study. Am J Hypertens 12 (1999) 304-310
30. Stevens P.A., and Brown M.J. Genetic variability of the ET-1 and the ETA receptor genes in essential hypertension. J Cardiovasc Pharmacol 26 (1995) S9-S12
31. Herrmann S.M., Schmidt-Petersen K., Pfeifer J., et al. A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy. Eur Heart J 22 (2001) 1948-1953
32. Lajemi M., Gautier S., Poirier O., et al. Endothelin gene variants and aortic and cardiac structure in never-treated hypertensives. Am J Hypertens 14 (2001) 755-760
33. Shesely E.G., Maeda N., Kim H.S., et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 93 (1996) 13176-13181
34. Huang P.L., Huang Z., Mashimo H., et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377 (1995) 239-242
35. Fagan K.A., Tyler R.C., Sato K., et al. Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. Am J Physiol Lung Cell Mol Physiol 277 (1999) L472-L478
36. Rudic R.D., Shesely E.G., Maeda N., Smithies O., Segal S.S., and Sessa W.C. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 101 (1998) 731-736
37. Quinlan T.R., Li D., Laubach V.E., Shesely E.G., Zhou N., and Johns R.A. eNOS-deficient mice show reduced pulmonary vascular proliferation and remodeling to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 279 (2000) L641-L650
38. Giaid A., and Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333 (1995) 214-221
39. Rossi G.P., Taddei S., Virdis A., et al. The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol 41 (2003) 938-945
40. Veldman B.A., Spiering W., Doevendans P.A., et al. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 20 (2002) 2023-2027
41. Yoshimura M., Nakayama M., Shimasaki Y., et al. A T-786→C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene and coronary arterial vasomotility. Am J Cardiol 85 (2000) 710-714
42. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 21 (2000) 90-113
43. Spiegel A.M., and Weinstein L.S. Inherited diseases involving g proteins and g protein-coupled receptors. Annu Rev Med 55 (2004) 27-39
44. sα gene with essential hypertension and response to β-blockade. Hypertension 34 (1999) 8-14
45. Hengstenberg C., Schunkert H., Mayer B., et al. Association between a polymorphism in the G protein β3 subunit gene (GNB3) with arterial hypertension but not with myocardial infarction. Cardiovasc Res 49 (2001) 820-827
46. Feldman R.D., Tan C.M., and Chorazyczewski J. G protein alterations in hypertension and aging. Hypertension 26 (1995) 725-732
47. Frey U.H., Alakus H., Wohlschlaeger J., et al. GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res 11 (2005) 5071-5077
48. Siffert W. G protein polymorphisms in hypertension, atherosclerosis, and diabetes. Annu Rev Med 56 (2005) 17-28
49. Rueckschloss U., Duerrschmidt N., and Morawietz H. NADPH oxidase in endothelial cells: impact on atherosclerosis. Antioxid Redox Signal 5 (2003) 171-180
50. Cai H., and Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87 (2000) 840-844
51. Li J.M., and Shah A.M. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem 277 (2002) 19952-19960
52. Xu J.W., Ikeda K., and Yamori Y. Genistein inhibits expressions of NADPH oxidase p22phox and angiotensin II type 1 receptor in aortic endothelial cells from stroke-prone spontaneously hypertensive rats. Hypertens Res 27 (2004) 675-683
53. Zafari A.M., Davidoff M.N., Austin H., et al. The A640G and C242T p22(phox) polymorphisms in patients with coronary artery disease. Antioxid Redox Signal 4 (2002) 675-680
54. Inoue N., Kawashima S., Kanazawa K., Yamada S., Akita H., and Yokoyama M. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 97 (1998) 135-137
55. San José G., Moreno M.U., Oliván S., et al. Functional effect of the p22phox-930A/G polymorphism on p22phox expression and NADPH oxidase activity in hypertension. Hypertension 44 (2004) 163-169
56. Zalba G., San José G., Moreno M.U., Fortuño A., and Díez J. NADPH oxidase-mediated oxidative stress: genetic studies of the p22(phox) gene in hypertension. Antioxid Redox Signal 7 (2005) 1327-1336
57. Marcos E., Fadel E., Sanchez O., et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 94 (2004) 1263-1270
58. Eddahibi S., Hanoun N., Lanfumey L., et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 105 (2000) 1555-1562
59. MacLean M.R., Sweeney G., Baird M., McCulloch K.M., Houslay M., and Morecroft I. 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 119 (1996) 917-930
60. Eddahibi S., Raffestin B., Hamon M., and Adnot S. Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension?. J Lab Clin Med 139 (2002) 194-201
61. Lesch K.P., Bengel D., Heils A., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274 (1996) 1527-1531
62. Eddahibi S., Humbert M., Fadel E., et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108 (2001) 1141-1150
63. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 (1992) 70-75
64. Tuder R.M., Cool C.D., Geraci M.W., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159 (1999) 1925-1932
65. Geraci M.W., Gao B., Shepherd D.C., et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 103 (1999) 1509-1515
66. Nakayama T., Soma M., Takahashi Y., Uwabo J., Izumi Y., and Kanmatsuse K. Novel polymorphic CA/TG repeat identified in the human prostacyclin synthase gene. Hum Hered 47 (1997) 176-177
67. Chevalier D., Cauffiez C., Bernard C., et al. Characterization of new mutations in the coding sequence and 5'-untranslated region of the human prostacyclin synthase gene (CYP8A1). Hum Genet 108 (2001) 148-155
68. Stitham J., Stojanovic A., and Hwa J. Impaired receptor binding and activation associated with a human prostacyclin receptor polymorphism. J Biol Chem 277 (2002) 15439-15444
69. Archer S.L., Souil E., Dinh-Xuan A.T., et al. Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J Clin Invest 101 (1998) 2319-2330
70. Archer S.L., Wu X.C., Thébaud B., et al. Preferential expression and function of voltage-gated, O2-sensitive K+ channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: ionic diversity in smooth muscle cells. Circ Res 95 (2004) 308-318
71. Yuan J.X.J., Aldinger A.M., Juhaszova M., et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98 (1998) 1400-1406
72. Yuan X.J., Wang J., Juhaszova M., Gaine S.P., and Rubin L.J. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 351 (1998) 726-727
73. Remillard C.V., Tigno D.D., Platoshyn O., et al. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol 292 (2007) C1837-C1853
74. Wilkins M.R., Nunez D.J., and Wharton J. The natriuretic peptide family: turning hormones into drugs. J Endocrinol 137 (1993) 347-359
75. Klinger J.R., Petit R.D., Curtin L.A., et al. Cardiopulmonary responses to chronic hypoxia in transgenic mice that overexpress ANP. J Appl Physiol 75 (1993) 198-205
76. Jin H., Yang R.H., Chen Y.F., Jackson R.M., and Oparil S. Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia. J Clin Invest 85 (1990) 115-120
77. Rubattu S., Bigatti G., Evangelista A., et al. Association of atrial natriuretic peptide and type A natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol 48 (2006) 499-505
78. Rubattu S., Stanzione R., Di Angelantonio E., et al. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke 35 (2004) 814-818
79. Rehemudula D., Nakayama T., Soma M., et al. Structure of the type B human natriuretic peptide receptor gene and association of a novel microsatellite polymorphism with essential hypertension. Circ Res 84 (1999) 605-610
80. Weinshilboum R. Inheritance and drug response. N Engl J Med 348 (2003) 529-537
81. Evans W.E., and McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348 (2003) 538-549
82. Roses A.D. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 5 (2004) 645-656
83. Papaioannou A.I., Kostikas K., Kollia P., and Gourgoulianis K.I. Clinical implications for vascular endothelial growth factor in the lung: friend or foe?. Respir Res 7 (2006) 128
84. Eddahibi S., Humbert M., Sediame S., et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension: effect of prostacyclin therapy. Am J Respir Crit Care Med 162 (2000) 1493-1499
85. Voelkel N.F., Douglas I.S., and Nicolls M. Angiogenesis in chronic lung disease. Chest 131 (2007) 874-879
86. Lee S.D., Shroyer K.R., Markham N.E., Cool C.D., Voelkel N.F., and Tuder R.M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 101 (1998) 927-934
87. Tuder R.M., Chacon M., Alger L., et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Path 195 (2001) 367-374
88. Campbell A.I., Zhao Y., Sandhu R., and Stewart D.J. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 104 (2001) 2242-2248
89. Zhao Y.D., Courtman D.W., Ng D.S., et al. Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer. Am J Respir Cell Mol Biol 35 (2006) 182-189
90. Merklinger S.L., Jones P.L., Martinez E.C., and Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 112 (2005) 423-431
91. Hattori Y., Shimoda M., Okamoto S., Satoh T., Kakimoto T., and Ikeda Y. Pulmonary hypertension and thalidomide therapy in multiple myeloma. Br J Haematol 128 (2005) 885-887
92. Antonioli E., Nozzoli C., Gianfaldoni G., et al. Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma. Ann Oncol 16 (2005) 1849-1850
93. Vescovo G., Ravara B., Angelini A., et al. Effect of thalidomide on the skeletal muscle in experimental heart failure. Eur J Heart Fail 4 (2002) 455-460
94. Koutouzis M., Nomikos A., Nikolidakis S., et al. Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens. Atherosclerosis 192 (2007) 457-463
95. Girgis R.E., Li D., Zhan X., et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 285 (2003) H938-H945
96. Girgis R.E., Ma S.F., Ye S., et al. Differential gene expression in chronic hypoxic pulmonary hypertension: effect of simvastatin treatment. Chest 128 (2005) 579S
97. Girgis R.E., Mozammel S., Champion H.C., et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 292 (2007) L1105-L1110
98. McMurtry M.S., Bonnet S., Michelakis E.D., Bonnet S., Haromy A., and Archer S.L. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamycin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol 293 (2007) L933-L940
99. Kao P.N. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 127 (2005) 1446-1452
100. Cilley J.C., Barfi K., Benson III A.B., and Mulcahy M.F. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 7 (2007) 739-749
101. Willett C.G., Duda D.G., Czito B.G., Bendell J.C., Clark J.W., and Jain R.K. Targeted therapy in rectal cancer. Oncology (Williston Park) 21 (2007) 1055-1065
102. Zhong H., and Bowen J.P. Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem 7 (2007) 1379-1393
103. Moreno-Vinasco L., Gomberg-Maitland M., Maitland M.L., et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics 33 (2008) 278-291
104. Weis M., Heeschen C., Glassford A.J., and Cooke J.P. Statins have biphasic effects on angiogenesis. Circulation 105 (2002) 739-745
105. Burke S.E., Lubbers N.L., Chen Y.W., et al. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J Cardiovasc Pharmacol 33 (1999) 829-835
106. Humar R., Kiefer F.N., Berns H., Resink T.J., and Battegay E.J. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16 (2002) 771-780
107. Nishimura T., Faul J.L., Berry G.J., Veve I., Pearl R.G., and Kao P.N. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 163 (2001) 498-502
108. Paddenberg R., Stieger P., von Lilien A.L., et al. Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respir Res 8 (2007) 15
109. Hervé P., Humbert M., Sitbon O., et al. Pathobiology of pulmonary hypertension: the role of platelets and thrombosis. Clin Chest Med 22 (2001) 451-458
110. Schermuly R.T., Dony E., Ghofrani H.A., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115 (2005) 2811-2821
111. Perros F., Montani D., Dorfmüller P., et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178 (2008) 81-88
112. Ghofrani H.A., Seeger W., and Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353 (2005) 1412-1413
113. Patterson K.C., Weissmann A., Ahmadi T., and Farber H.W. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 145 (2006) 152-153
114. Souza R., Sitbon O., Parent F., Simonneau G., and Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 61 (2006) 736
115. Cowan K.N., Heilbut A., Humpl T., Lam C., Ito S., and Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 6 (2000) 698-702
116. Cowan K.N., Jones P.L., and Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 105 (2000) 21-34
117. Campbell A.I., Kuliszewski M.A., and Stewart D.J. Cell-based gene transfer to the pulmonary vasculature: endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension [see comments]. Am J Respir Cell Mol Biol 21 (1999) 567-575
118. Zhao Y.D., Campbell A.I., Robb M., Ng D., and Stewart D.J. Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circ Res 92 (2003) 984-991
119. Babaei S., and Stewart D.J. Overexpression of endothelial NO synthase induces angiogenesis in a co-culture model. Cardiovasc Res 55 (2002) 190-200
120. Cooke J.P. NO and angiogenesis. Atheroscler Suppl 4 (2003) 53-60
121. Ziche M., Morbidelli L., Choudhuri R., et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 99 (1997) 2625-2634
122. Zhao Y.D., Courtman D.W., Deng Y., Kugathasan L., Zhang Q., and Stewart D.J. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 96 (2005) 442-450
123. Asahara T., and Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol 287 (2004) C572-C579
124. Steward C.G., Pellier I., Mahajan A., et al. Severe pulmonary hypertension: a frequent complication of stem cell transplantation for malignant infantile osteopetrosis. Br J Haematol 124 (2004) 63-71
125. Grigg A., Buchanan M., and Whitford H. Late-onset pulmonary arterial hypertension in association with graft-versus-host disease after allogeneic stem-cell transplantation. Am J Hematol 80 (2005) 38-42
126. Massoud T.F., and Gambhir S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17 (2003) 545-580
127. Serganova I., and Blasberg R. Reporter gene imaging: potential impact on therapy. Nucl Med Biol 32 (2005) 763-780
128. Peñuelas I., Haberkorn U., Yaghoubi S., and Gambhir S.S. Gene therapy imaging in patients for oncological applications. Eur J Nucl Med Mol Imaging 32 (2005) S384-S403
129. Gaine S.P., and Rubin L.J. Primary pulmonary hypertension. Lancet 352 (1998) 719-725
130. Chin K.M., Kim N.H., and Rubin L.J. The right ventricle in pulmonary hypertension. Coron Artery Dis 16 (2005) 13-18
131. Parmley W.W., Tyberg J.V., and Glantz S.A. Cardiac dynamics. Annu Rev Physiol 39 (1977) 277-299
132. Piene H. Pulmonary arterial impedance and right ventricular function. Physiol Rev 66 (1986) 606-652
133. Kelly R.P., Ting C.T., Yang T.M., et al. Effective arterial elastance as index of arterial vascular load in humans. Circulation 86 (1992) 513-521
134. Janssens S., Pokreisz P., Schoonjans L., et al. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 94 (2004) 1256-1262
135. Moens A.L., Takimoto E., Tocchetti C.G., et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 117 (2008) 2626-2636
136. Chin K.M., Kim N.H., and Rubin L.J. The right ventricle in pulmonary hypertension. Coron Artery Dis 16 (2005) 13-18